Key result
Treatment with n-3 PUFA improved baseline lipid profiles and adiponectin levels, and improved all insulin resistance parameters after an oral fat load compared to placebo.
Why the study?
Does n-3 PUFA improve lipid profile and insulin resistance biomarkers compared to placebo?
Population
Patients (no specific condition, demographics, or sample size detailed in the abstract)
Comparison
n-3 PUFA 1 g three times a day, during meals… vs Placebo
Design
RCT
Follow-up
6 months
Authors
Loading...
n-3 PUFA may aid metabolic management in at-risk patients; extends RCT evidence to postprandial insulin resistance.
RCT
Does n-3 PUFA improve lipid profile and insulin resistance biomarkers compared to placebo?
n-3 PUFA supplementation improves baseline lipid profiles and post-prandial insulin resistance parameters, suggesting potential metabolic and cardiovascular benefits.
Derosa et al. (2011) reported an RCT. n-3 PUFA vs. placebo was evaluated on lipid profile and insulin resistance biomarkers. Treatment with n-3 PUFA improved baseline lipid profiles and adiponectin levels, and improved all insulin resistance parameters after an oral fat load compared to placebo.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: